Overview
- A randomized, placebo‑controlled phase 2 trial of acmopatide (CT‑868) enrolled 111 adults with type 1 diabetes and BMI ≥27 kg/m² and treated them for 16 weeks with 1.8 mg, 4.1 mg, 6.6 mg or placebo.
- The 4.1 mg dose produced a statistically significant HbA1c reduction at 16 weeks versus placebo, and higher doses showed dose‑dependent benefits in continuous glucose metrics.
- Participants lost substantial weight on active doses (about 6.4–6.7% with the 4.1 mg and 6.6 mg doses versus a 0.3% gain with placebo) and insulin use fell, with the 6.6 mg group reducing total daily insulin by roughly 15 units.
- Safety findings were dominated by mostly mild-to-moderate gastrointestinal side effects such as nausea and diarrhea, with no level‑3 hypoglycemia or diabetic ketoacidosis reported during the 16‑week study.
- Roche, which acquired sponsor Carmot during the program, announced it will not advance acmopatide to a phase 3 type 1 diabetes program, leaving the clinical and regulatory pathway for incretin therapies in type 1 diabetes unresolved while other companies pursue their own trials.